New Partnerships & Brand Loyalty - Research Report on Acura Pharmaceuticals, Élan Corp, Hospira, Alkermes and Valeant

Fri Mar 8, 2013 8:02am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130308:nPn3086435


NEW YORK,  March 8, 2013  /PRNewswire/ --

Today, Investors Alliance announced new research reports highlighting Acura
Pharmaceuticals, Inc. (NASDAQ: ACUR), Élan Corporation, Plc (NYSE: ELN),
Hospira, Inc. (NYSE: HSP), Alkermes Plc. (NASDAQ: ALKS) and Valeant
Pharmaceuticals Intl Inc. (NYSE: VRX). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Acura Pharmaceuticals, Inc. Research Report

Acura Pharmaceuticals enters the chain drug store market via its new next
generation pseudoephedrine with abuse deterrent technology.
Nexafed[pseudoephedrine hydrochloride (HCI)] - a 30 mg immediate-release
pseudoephedrine product that combines effective nasal-congestion relief with a
unique technology that disrupts the conversion of pseudoephedrine into the
dangerous drug, methamphetamine (meth) - will now be stocked by KERR DRUG chain
of stores. "We are extremely pleased with KERR DRUG's decision to join the fight
against methamphetamine abuse by stocking Nexafed," said  Robert B. Jones,
president and chief executive officer of Acura Pharmaceuticals. "We anticipated
early interest in Nexafed from independent pharmacies but it is rewarding that
forward-looking drug chains like KERR DRUG are stepping up to make a difference
in the communities in which they operate." The Full Research Report on Acura
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/b2f1_ACUR]

Élan Corporation, PLC. Research Report

A unique cash flow dividend policy has been approved by the Board of Élan
Corporation that'll enable its shareholders to benefit directly from the long
term cash flow generated by Tysabri. The dividend program will be directly
linked to Tysabri market performance calculated as a percentage of the Tysabri
royalty paid to Élan from Biogen Idec as a result of the recently announced
Tysabri restructuring. The initial percentage to be paid out directly to
shareholders is 20 % of those royalties. The uncapped dividend cash payments
give shareholders the right to enjoy unlimited participation in the upside from
the Tysabri sales increase. The payments will be done in twice-yearly
installments, with the first payment expected in the fourth quarter of 2013. The
Full Research Report on Élan Corporation, PLC. - including full detailed
breakdown, analyst ratings and price targets - is available to download free of
charge at: [http://www.investors-alliance.com/r/full_research_report/294e_ELN]

Hospira, Inc. Research Report

Royce R. Bedward  joins Hospira as its new corporate vice president, general
counsel and secretary effective immediately. "Royce is an accomplished lawyer
and integrity-driven business leader with more than 10 years of experience in
the healthcare field and a proven track record of success at Hospira," said Mr. 
F. Michael Ball, Hospira CEO. "We look forward to Royce's many additional
contributions, while thanking Brian for his continued service and counsel.
Working together, I'm confident that their strong leadership abilities will help
position Hospira for a stronger future of sustainable, long-term growth and
drive greater value for our stakeholders. "Mr. Bedward will oversee the
company's legal department, including litigation, benefits, labor and
employment, intellectual property, governance, securities and transactional
matters. Hospira, Inc. is the world's leading provider of injectable drugs and
infusion technologies. Through its broad, integrated portfolio, Hospira is
uniquely positioned to Advance Wellness by improving patient and caregiver
safety while reducing healthcare costs. The company is headquartered in  Lake
Forest, Ill., and has approximately 16,000 employees. The full Research Report
on Hospira, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/44b1_HSP]

Alkermes Plc. Research Report

It was a good third quarter for Alkermes as non-GAAP diluted EPS grew to  $0.34 
from  $0.10, prompting improved financial expectations for its fiscal year 2013.
"With results now spanning an entire year, the power of Alkermes Plc is becoming
evident. Our strong financial performance was driven by our five key commercial
products, which grew 33% year-over-year," commented  James Frates, Chief
Financial Officer of Alkermes. "Today, we are again improving our financial
expectations for fiscal 2013, based on our robust operational performance across
the business. We now expect Alkermes to generate between  $135 million and $155
million  in non-GAAP net income this fiscal year." Manufacturing and royalty
revenues from the company's long-acting atypical antipsychotic franchise 
RISPERDAL, CONSTA, and  INVEGA SUSTENNA/XEPLION  amount to  $52.5 million. Net
sales, and royalty and manufacturing of its other products also contributed to
the increase in revenue for the company. The Full Research Report on Alkermes
Plc. - including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/2f8e_ALKS]

Valeant Pharmaceuticals Intl Inc. Research Report

It was a healthy 2012 Q4 for Valeant Pharmaceuticals as the company posted good
figures, thanks to organic growth. For Q4, total revenue amounted to  $986
million, a 43% increase over the prior year with same store sales up by 7%. For
the full year, the company enjoys a 44% increase in total revenue amounting to 
$3.55 billion  versus 2011's  $2.46 billion. The company's U.S. Dermatology
business has shown solid growth, thanks to the sales performance of  Zovirax,
Retin-A Micro, Acanya, Carac  and  CeraVe.  Valeant's other portfolio also
delivered positive results, reflecting the diminishing year over year negative
impact from generic competitors of  Wellburtin XL, Ultram  and  Cardizem CD. The
Full Research Report on Valeant Pharmaceuticals Intl Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to download
free of charge at:
[http://www.investors-alliance.com/r/full_research_report/8d49_VRX]

Consider Investors Alliance

Tired of hearing about the latest, greatest trade opportunity... only to realize
that the ship has long sailed? You need a strong, informative community in your
arsenal. Join the group that has been consistently identifying momentous
situations as they develop - long before they become the next top news on major
financial networks.

Contact:  Patricia Byers

Email:  press@investors-alliance.com

Main: +1-(408)-745-7826

SOURCE  Investors-Alliance

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.